BMO Capital Thinks Medtronic’s Stock is Going to Recover

By Jason Carr

BMO Capital analyst Joanne Wuensch reiterated a Buy rating on Medtronic (NYSE: MDT) yesterday. The company’s shares opened today at $73.26, close to its 52-week low of $71.03.

According to, Wuensch is a 3-star analyst with an average return of 2.9% and a 54.4% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Medtronic is Strong Buy and the average price target is $88.17, representing a 20.4% upside.

In a report issued on November 9, Jefferies also reiterated a Buy rating on the stock with a $100 price target.

Medtronic’s market cap is currently $101.7B and has a P/E ratio of 28.64. The company has a book value ratio of 2.0012.